WALTHAM, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced new data from two abstracts presented at the American Society of Nephrology (ASN) Kidney Week 2019 in Washington, D.C. November 5 -10, 2019.
Bay Street News